Company Overview and News
As part of the government's industrialisation drive in the state, Tamil Nadu chief minster J Jayalalithaa on Friday launched a slew of projects as well laid foundation stones...
According to market experts, falling prices of major cost components such as steel, aluminium and rubber will support margins of two-wheeler companies in the next few years.
Stocks of IndiGo's parent InterGlobe Aviation will be in focus as the budget carrier has said that it is in discussions with aircraft maker Airbus regarding the delay and revised schedule for the delivery of new planes.
The company reported net profit of Rs 388.15 crore for the quarter ended December 31, compared with Rs 323.51 crore for the same period a year ago. MRF saw its cost of raw materials go down 10.7% to Rs 1813.51 crore.
Tyre maker MRF today reported 19.98 per cent rise in its standalone net profit at Rs 3
Net profit rose 19.8% to Rs388.15 crore, lower than expected, hurt by weak demand
MRF Ltd has posted a net profit of Rs 388.1 crore for the quarter ended December 31, 2015 as compared to Rs 323.5 crore for the quarter ended December 31, 2014. Total Income has decreased from Rs 3378.6 crore for the quarter ended December 31, 2014
MRF has renewed its contract with ICC of global partner for sixth edition of ICC World Twenty-20 India 2016
MRF Ltd has become a global partner for International Cricket Council (ICC) by signing
Beneficiaries of the oil rout figure prominently in one of the funds managed by Birla Sun Life AMC Co-Chief CIO Mahesh Patil...
The previous-generation Endeavour was quite a brutish SUV, and while the new one has more rounded proportions and overall stance, Ford hasn’t diluted its rugged appeal or performance
Stocks impacted by the yuan depreciation include Tata Motors. Shares of the auto major tanked 5 percent intraday on Thursday, falling over 12 percent this week alone...
The previous-generation Ford Endeavour was always quite a brutish SUV and while the new one has sharper proportions and overall stance, it hasn't become diluted in its overall appeal
This morning, we came across a piece by Fran Kinniry of Vanguard suggesting that bonds lack investors' respect when it comes time to talk diversification, complete with the required Rodney Dangerfield
During the last few months, I have provided articles on the stocks, including exchange-listed closed end funds [CEFs], that pay their dividends monthly. Many income investors are looking for monthly p
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...